CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 474 enrolled
Drug / intervention
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibodydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02458638
NCT02458638Phase 2Completed
CompareCT.gov

An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors

Hoffmann-La Roche·interventional·Posted Jun 1, 2015·Updated Jun 4, 2021

In Brief

A Phase 2 clinical trial evaluating Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody for Tumors. Completed, enrolled 474 participants across 48 sites in 18 countries.

Detailed Summary

The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
CountriesAustria, Brazil, Canada, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Russia, Spain, Switzerland, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 1, 2015
Enrollment StartJul 16, 2015
Primary CompletionApr 4, 2018
Study CompletionJul 28, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.1 years ago

Interventions

Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibodydrug

Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.